Lexaria Bioscience Announces $2 Million Stock Offering to Advance Drug Delivery Technology

Lexaria Bioscience Corp. has announced a registered direct offering of 2 million shares of common stock at $1.00 per share, generating $2 million in gross proceeds to support the company's research and development initiatives. This financial transaction, expected to close around April 28, 2025, represents a strategic move to maintain research momentum and pursue technological developments in drug delivery solutions. The offering is being conducted under a previously filed shelf registration statement that was declared effective by the Securities and Exchange Commission on January 30, 2025, providing the company with flexibility in executing its capital-raising strategy.

H.C. Wainwright & Co. serves as the exclusive placement agent for this offering, facilitating the transaction under standard closing conditions. The company plans to allocate the net proceeds toward working capital and general corporate purposes, ensuring continued advancement of its innovative technologies. This funding approach allows Lexaria to strategically manage its financial resources while pursuing long-term growth objectives in the competitive pharmaceutical technology sector.

The capital infusion comes at a critical time for Lexaria as it continues to develop its proprietary DehydraTECH drug delivery platform. This technology has demonstrated significant capabilities in improving bio-absorption and potentially reducing side effects of various pharmaceutical compounds. With 48 patents already granted worldwide and additional patents pending, the company maintains a strong intellectual property position in the drug delivery space. The funding will support ongoing research efforts to enhance the platform's capabilities and explore new applications across different therapeutic areas.

This offering represents more than just a financial transaction; it signifies investor confidence in Lexaria's technology and growth potential. The ability to raise capital through a registered direct offering under an effective shelf registration demonstrates the company's strategic financial planning and regulatory compliance. As Lexaria continues to advance its drug delivery technology, this funding provides the necessary resources to maintain research momentum, protect intellectual property, and potentially expand the commercial applications of the DehydraTECH platform in the global pharmaceutical market.